Management Team

Management Team


  • Andrey Semechkin, PhD.

    Chief Executive Officer and Co-Chairman of the Board

    Professor Semechkin is a specialist in system analysis, strategic planning and corporate management. He is a member of the Russian Academy of Sciences and has been Deputy Director of Institute of System Analysis since 2004. Professor Semechkin was awarded the Russian Government Award in Science and Technology in 2006 and has written several scientific books. He has over 20 years of experience creating and managing businesses across different industries and scientific sectors.

  • Jennifer Stephens, CPA

    Acting Chief Financial Officer

    On August 24, 2017, the Board of Directors of the Company appointed Jennifer Stephens as its acting Chief Financial Officer effective August 25, 2017. Ms. Stephens has served in the Director of Finance position since February 2017. Ms. Stephens has been providing accounting and finance services as a consultant since April 2013. She has served an extensive number of companies in various management level accounting positions assisting with technical accounting research, SEC filings, and SOX 404 implementations and compliance. Preceding her years as an accounting and finance consultant, Ms. Stephens worked with Ernst & Young LLP in a senior supervisory role in the San Diego audit practice where she worked with clients ranging in size from closely held, venture capital backed start-up companies to billion dollar SEC registrants. Ms. Stephens received a B.A. in Business Economics and Accounting from the University of California, Santa Barbara and is a licensed CPA.

  • Russell Kern, PhD.

    Executive Vice President, Chief Scientific Officer

    Dr. Kern was trained in medical genetics, embryology and stem cell biology. He holds a Ph.D. degree in Human Physiology from the Russian Academy of Medical Sciences and has broad expertise in neuroscience, and was part of the team, along with scientists from the NYU Medical School that elucidated the physiological changes that occur in the brains of Parkinson’s disease patients. Dr. Kern directs ISCO’s R&D programs including stem cell derivation, differentiation and the pre-clinical and clinical evaluation of stem cell derived cells and tissue. He has developed a general method of deriving highly pure populations of neural stem cells and dopaminergic neurons from pluripotent stems cells that is novel, practical and suitable for use in a clinical setting. Dr. Kern is a well-known speaker on stem cell biology, including the use of stem cells for neurology and skin regeneration. He has more than 40 publications in the field of Parkinson’s disease and stem cell biology and he is an active member of the American Academy of Neurology, the Society for Neuroscience and the International Society for Stem Cell Research.

  • Francisco Bustamante

    President of Lifeline Cell Technology, LLC

    Mr. Bustamante has over eighteen years of experience in Operations of Biotechnology companies. His experience includes senior management positions in the areas of manufacturing, procurement, planning, warehousing, distribution and project management. Mr. Bustamante has an excellent understanding of the manufacture and logistics of cell culture products, biological instruments, molecular biology kits and diagnostics. He has led key projects in the areas of manufacturing resource planning (MRP) systems implementation, ISO compliance and product development. His industry experience includes Clonetics, BioWhittaker (Cambrex), Digene and Meso Scale Diagnostics. Mr. Bustamante received his BS degree in Biology from the University of San Diego and his MBA degree from Frostburg State University. He has been with Lifeline Cell Technology since 2007.

  • Sophia Garnette, J.D.

    Vice President, Legal Affairs & Operations

    Ms. Garnette received her J.D. from the University of Miami School of Law and has experience in various aspects of corporate and biotechnology law, regulatory affairs, project management, and business operations. After joining the Company in March 2011, she has held a variety of business and legal roles, including in-house counsel, advisor to the CEO, and Vice Chairman of the Board of Directors for Lifeline Skin Care. Ms. Garnette holds a Bachelor’s degree in Economics from San Francisco State University and has worked in the finance industry prior to beginning her legal career.

  • Jeremy Hammond

    Director of Quality Control

    Mr Hammond has over eighteen years of experience developing human cell based products and the quality control systems critical for their manufacture. He created and implemented the quality control systems that were responsible for making Clonetics products world renown for consistency and reproducibility. These quality control systems are the standard for companies currently manufacturing human cell based products. Mr. Hammond is expert in the field of both serum-containing and serum-free media formulations and in the purification of human cells, fields critical for therapeutic applications of cell culture technology.

  • Glenn Sherman, PhD.

    Director of Chemistry Manufacturing and Controls (CMC)

    Dr. Sherman has over 20 years of experience in Regulatory Affairs. He worked as a primary microbiology reviewer at the US FDA where he lead pre-IND reviews in the Division of Antiviral Drug Products. After leaving the FDA Dr. Sherman held regulatory positions at Pfizer and Johnson & Johnson, where he was CMC regulatory lead for biologics products and successfully managed IND related activities for the biologics clinical, nonclinical and CMC teams. Dr. Sherman holds a PhD in Microbiology and Immunology from the University of North Carolina, Chapel Hill, NC.